191 related articles for article (PubMed ID: 21651449)
1. Sitagliptin: a review.
Subbarayan S; Kipnes M
Expert Opin Pharmacother; 2011 Jul; 12(10):1613-22. PubMed ID: 21651449
[TBL] [Abstract][Full Text] [Related]
2. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
Abel T; Fehér J
Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
4. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
Bailey CJ; Green BD; Flatt PR
Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.
Herman GA; Stein PP; Thornberry NA; Wagner JA
Clin Pharmacol Ther; 2007 May; 81(5):761-7. PubMed ID: 17392725
[TBL] [Abstract][Full Text] [Related]
7. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
Gallwitz B
Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
[No Abstract] [Full Text] [Related]
8. [Sitagliptin].
Taéron C
Rev Infirm; 2008 Oct; (144):46-8. PubMed ID: 19009789
[No Abstract] [Full Text] [Related]
9. [Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin].
Perusicová J
Vnitr Lek; 2007 Oct; 53(10):1109-13. PubMed ID: 18072437
[TBL] [Abstract][Full Text] [Related]
10. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
Srivastava S; Saxena GN; Keshwani P; Gupta R
J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
[TBL] [Abstract][Full Text] [Related]
11. [Sitagliptin in the treatment of type 2 diabetes: new data presented during the American Diabetes Association annual meeting (San Diego, California, June 2011)].
Rabasseda X
Drugs Today (Barc); 2011 Nov; 47 Suppl D():1-8. PubMed ID: 22439134
[TBL] [Abstract][Full Text] [Related]
12. DPP-4 inhibitors and their potential role in the management of type 2 diabetes.
Barnett A
Int J Clin Pract; 2006 Nov; 60(11):1454-70. PubMed ID: 17073841
[TBL] [Abstract][Full Text] [Related]
13. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
[TBL] [Abstract][Full Text] [Related]
14. Managed care perspective on three new agents for type 2 diabetes.
VanDeKoppel S; Choe HM; Sweet BV
J Manag Care Pharm; 2008 May; 14(4):363-80. PubMed ID: 18500914
[TBL] [Abstract][Full Text] [Related]
15. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Miller S; St Onge EL
Ann Pharmacother; 2006; 40(7-8):1336-43. PubMed ID: 16868220
[TBL] [Abstract][Full Text] [Related]
16. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
Gallwitz B
Drugs Today (Barc); 2007 Oct; 43(10):681-9. PubMed ID: 17987221
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
18. [Incretin enhancer: sitagliptin].
Kondo M; Tanizawa Y
Nihon Rinsho; 2011 May; 69(5):859-63. PubMed ID: 21595272
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy of hyperglycemia.
Kulasa KM; Henry RR
Expert Opin Pharmacother; 2009 Oct; 10(15):2415-32. PubMed ID: 19743938
[TBL] [Abstract][Full Text] [Related]
20. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
Gallwitz B
Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]